Quarterly report · Q2
9989.TEDINET S100PMIV
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥339.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥648.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥326.8bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥18.5bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥17.9bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥18.8bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥34.7bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥18.2bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥18.5bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥18.3bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥12.7bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥23.9bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥12.5bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥12.7bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥12.5bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥337.1bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥325.8bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥313.5bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥108.0bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥105.2bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥229.1bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥220.6bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥213.3bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥94.5bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥89.3bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥94.5bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥89.3bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥90.3bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥86.5bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥21.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥31.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥16.8bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥12.0bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥20.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥8.9bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥4.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥8.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥4.1bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥108.81 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥54.94 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥204.02 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥106.54 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥48.36 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥108.81 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥204.01 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥106.53 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 68.0% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 67.7% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.0% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥24.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥24.7bn |
| jpcrp040300-q2r_E03226-000Discount Storereportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥143.9bn |
| jpcrp040300-q2r_E03226-000Discount Storereportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥143.9bn |
| jpcrp040300-q2r_E03226-000Discount Storereportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥5m |
| jpcrp040300-q2r_E03226-000Discount Storereportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥6.7bn |
| jpcrp040300-q2r_E03226-000Drug Storereportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥220.0bn |
| jpcrp040300-q2r_E03226-000Drug Storereportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥195.3bn |
| jpcrp040300-q2r_E03226-000Drug Storereportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥24.7bn |
| jpcrp040300-q2r_E03226-000Drug Storereportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥11.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥363.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥339.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥24.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥18.5bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥22.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥22.9bn |
| jpcrp040300-q2r_E03226-000Discount Storereportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥134.1bn |
| jpcrp040300-q2r_E03226-000Discount Storereportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥134.1bn |
| jpcrp040300-q2r_E03226-000Discount Storereportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥6m |
| jpcrp040300-q2r_E03226-000Discount Storereportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥6.1bn |
| jpcrp040300-q2r_E03226-000Drug Storereportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥215.5bn |
| jpcrp040300-q2r_E03226-000Drug Storereportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥192.6bn |
| jpcrp040300-q2r_E03226-000Drug Storereportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥22.9bn |
| jpcrp040300-q2r_E03226-000Drug Storereportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥11.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥349.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥326.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥22.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥17.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 480
| Item | Context | Value | Unit |
|---|---|---|---|
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E03226-000DiscountStoreReportableSegmentsMember | 6068000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 17928000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Operating income | Prior1YTDDuration | 17928000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E03226-000DrugStoreReportableSegmentsMember | 195297000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E03226-000DiscountStoreReportableSegmentsMember | 143925000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 339223000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 339223000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E03226-000DrugStoreReportableSegmentsMember | 24655000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E03226-000DiscountStoreReportableSegmentsMember | 5000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 24661000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -24661000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E03226-000DrugStoreReportableSegmentsMember | 219953000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E03226-000DiscountStoreReportableSegmentsMember | 143931000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 363884000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -24661000000 | JPY |
| Net sales | CurrentYTDDuration | 339223000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E03226-000DrugStoreReportableSegmentsMember | 11806000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E03226-000DiscountStoreReportableSegmentsMember | 6705000000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 18511000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Operating income | CurrentYTDDuration | 18511000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2022-11-14 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第60期第２四半期(自 2022年７月１日 至 2022年９月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社サンドラッグ | |
| Company name in english cover page | FilingDateInstant | SUNDRUG CO.,LTD. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 CEO 貞方 宏司 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都府中市若松町一丁目38番地の１ | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)042(369)6211（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)執行役員 管理部長 加藤 好伸 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都府中市若松町一丁目38番地の１ | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)042(369)6211（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)執行役員 管理部長 加藤 好伸 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E03226 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 99890 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社サンドラッグ | |
| Filer name in english | FilingDateInstant | SUNDRUG CO.,LTD. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |